We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA接受Outlook Therapeutics的上诉，将批准LYTENAVA——一种用于新生血管性AMD的标准化贝伐珠单抗。分析对anti-VEGF市场、定价和患者的影响。了解更多。
